# A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

> **NCT00922441** · PHASE2 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 92 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Fimasartan 60 mg group
- **DRUG:** Fimasartan 120 mg group
- **DRUG:** Reference (Valsartan 80 mg) group

## Key facts

- **NCT ID:** NCT00922441
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2018-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922441, "A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00922441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*